tag breast-cancer 
pharmaphorum
APRIL 27, 2022
AstraZeneca and Daiichi Sankyo have claimed a fifth breakthrough designation from the FDA for Enhertu, shortly after showing the drug extended survival in patients with HER2-low metastatic breast cancer. The post Enhertu gets breakthrough tag in HER2-low breast cancer appeared first on.
Pharmaceutical Technology
AUGUST 1, 2023
Vepdegestrant was awarded the Innovation Passport designation for treating advanced or metastatic breast cancer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
OCTOBER 29, 2021
Take two recently-approved immunotherapies for triple negative breast cancer (TNBC), put them together, and what do you get? “This helps further our ambition of displacing chemotherapy with Trodelvy to improve outcomes for people living with cancer,” said Gilead’s chief medical officer Merdad Parsey.
Pharma Tutor
DECEMBER 27, 2021
AROMATASE INHIBITORS IN BREAST CANCER. Read more about AROMATASE INHIBITORS IN BREAST CANCER Log in or register to post comments Read more about AROMATASE INHIBITORS IN BREAST CANCER Log in or register to post comments About Authors. MANISHA KOTADIYA*, JAYDEEP SAVALIYA. DOWNLOAD AS PDF.
Drug Discovery World
MARCH 2, 2023
A new paper has solved the 20-year mystery of how epigenetic modifications act as traffic lights to control gene expression and could ultimately speed up the development of a new class of epigenetic cancer drugs. Epigenetics is still largely unexplored and referred to as the ‘dark matter’ of the genome.
pharmaphorum
JANUARY 11, 2022
It has since been joined by other products in the software as a medical device (SaaMD) category, including Pear Therapeutics’ alcohol-use disorder candidate Pear-009 and another Blue Note DTx, codenamed BNT001, which is also being tested for anxiety and depression in cancer patients.
pharmaphorum
DECEMBER 23, 2021
Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer. The post FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tag appeared first on. Daiichi Sankyo and AZ are close collaborators in the ADC arena.
Expert insights. Personalized for you.
58 
Let's personalize your content